Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

vTv Therapeutics (VTVT) EBT (2016 - 2025)

vTv Therapeutics' EBT history spans 12 years, with the latest figure at -$7.1 million for Q4 2025.

  • For Q4 2025, EBT fell 60.87% year-over-year to -$7.1 million; the TTM value through Dec 2025 reached -$31.1 million, down 37.49%, while the annual FY2025 figure was -$31.1 million, 37.49% down from the prior year.
  • EBT for Q4 2025 was -$7.1 million at vTv Therapeutics, up from -$10.3 million in the prior quarter.
  • Across five years, EBT topped out at -$841000.0 in Q2 2021 and bottomed at -$10.3 million in Q3 2025.
  • The 5-year median for EBT is -$6.0 million (2021), against an average of -$6.1 million.
  • The largest YoY upside for EBT was 83.15% in 2021 against a maximum downside of 690.11% in 2021.
  • A 5-year view of EBT shows it stood at -$9.5 million in 2021, then soared by 35.78% to -$6.1 million in 2022, then rose by 27.08% to -$4.4 million in 2023, then grew by 0.09% to -$4.4 million in 2024, then tumbled by 60.87% to -$7.1 million in 2025.
  • Per Business Quant, the three most recent readings for VTVT's EBT are -$7.1 million (Q4 2025), -$10.3 million (Q3 2025), and -$7.4 million (Q2 2025).